Stock Ratings / Health Care / STTK / options

NGNE (36) EVO (57) ACRS (31) DRUG (61) ⌘ Pro Terminal →

Shattuck Labs Inc. (STTK) Options Positioning, Max Pain & Unusual Sweeps

$5.72 -1.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.69

Shattuck Labs Inc. (STTK) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $574.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.69 (-0.45%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STTK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY STTK SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$5.97-9.2% Next Q

Q2 (-2Q)

Grade E$5.42+1.3% Next Q

Q3 (-1Q)

Grade E$5.49+4.2% Next Q

Current

Grade E$5.72-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STTK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STTK currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.28) and Max Pain ($6.01) forces dealer call-delta covering toward $8.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “STTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (STTK)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for STTK.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STTK)

✓Walkthrough of STTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

STTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.00%📐 HORIZONTAL RANGE

2026-10-30O $5.67H $5.74L $5.36C $5.72VOL 951.5K

RES: $8.87SUP: $5.03SMA50: $6.28SMA200: $6.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STTK Butterfly Map → + Track STTK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on STTK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STTK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for STTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STTK)

Health Care Rank #915 of 1016 ⚔️ NGNE vs STTK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STTK vs. NGNE, EVO, ACRS, DRUG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Shattuck Labs Inc. (STTK) ranks #915 by composite RQD confidence (31/100, grade E) and #428 by equity capitalization ($574.1M). Within this direct 5-issuer industry benchmark cohort, STTK leads on earnings valuation at N/A trailing P/E, while STTK leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. DRUG currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with STTK at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
STTK ACTIVE Shattuck Labs Inc.	E	31/100	—	—	-35.0%	-1.46%	$574.1M	Benchmark Subject
NGNE Neurogene Inc.	D-	36/100	—	—	-35.0%	-5.26%	$576.7M	/ngne-vs-sttk →
EVO Evotec SE	D+	57/100	—	—	—	-1.56%	$562.1M	/evo-vs-sttk →
ACRS Aclaris Therapeutics Inc.	E	31/100	—	73.3%	-35.0%	+0.76%	$587.3M	/acrs-vs-sttk →
DRUG Bright Minds Biosciences Inc.	C-	61/100	—	—	—	+2.48%	$556.7M	/drug-vs-sttk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001680367

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shattuck Labs Inc. (STTK) reported GAAP revenue of $1.0M (-82.5% vs. FY2024 revenue of $5.7M , and -39.6% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$39.9M, and free cash flow of -$40.0M (+34.0% YoY). On the balance sheet, STTK closed FY2025 with $91.0M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$48.8M	-$39.9M	-$40.0M	$91.0M	—
FY2024 (FY)	2024-12-31	$5.7M	-$75.4M	-$60.5M	-$60.6M	$91.0M	—
FY2023 (FY)	2023-12-31	$1.7M	-$87.3M	-$81.2M	-$81.2M	—	—

3. STTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Shattuck Labs Inc. (NASDAQ: STTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $5.72 (-1.46% 1D, market cap $574.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STTK ranks #915 in composite RQD confidence.

How does STTK compare to NGNE and EVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), STTK carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NGNE (Neurogene Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $576.7M) and EVO (Evotec SE) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $562.1M). Among the 5-stock peer group, STTK leads on earnings multiple (N/A) while STTK leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for STTK?

Per STTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001680367), Shattuck Labs Inc. generated $1.0M in revenue (-82.5% YoY), -$48.8M in net income, and -$40.0M in free cash flow against $91.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is STTK trading relative to its 50-day, 200-day, and 52-week technical levels?

STTK last traded at $5.72 (-1.46% on volume of 676,331 shares), positioning the stock -8.92% below its 50-day simple moving average ($6.28) and -5.30% below its 200-day simple moving average ($6.04). Across its 52-week range of $1.72 to $8.33, STTK sits at the 60.5% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.01 to $6.43).

STTK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is STTK's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for STTK.

Direct Sub-Reports: STTK RQD Cockpit STTK 12M Forecast STTK Earnings & Move STTK Dividends & DRIP STTK Insiders & 13F STTK Whale Options STTK Profit Sankey STTK News & Why